| HN Mirror

That's part of academic politics. Navigating grant funding is arguably one of the most important skills that a PHD program is supposed to teach given how important that is to the process of research.

Oncology has way way way more funding because there's a much bigger market for it - infectious diseases primarily affect poor people who aren't Americans so not much money in it. Even at the peak of covid I remember advisors warning phd applicants passionate about infectious diseases that the funding surge wasn't going to last and to be careful (which was right). Consider how moderna was originally founded as a vaccine company before almost completely shifting focus to oncology because that's where the money was. Obviously they swung back to vaccines when the pandemic showed up but now they're back focused on oncology.

Funding priorities are also set by the government - there's the cancer moonshot etc which means tons and tons of cancer funding. For universities new cancer treatments are quite valuable IP. And so on. Within a field it becomes very obvious where the funding and momentum is - what are the buzzwords everyone is putting in their grants and papers (nanotech? AI?), what types of publications are getting published int he big journals. Gene therapy came out of its winter after luxturna for example. Car-t was booming after the first approval there, entire departments were set up for it. Mrna stuff is super hot right now, but one of the researchers behind the core technology (that made her university like a billion dollars in royalties) was denied tenure and pushed out of academia when she originally developed the technology because it was considered not useful. First lab I worked in - the PI was fresh out of his postdoc and got hundreds of thousands of dollars in funding and his own lab and bought his own flow cytometer and everything (absolutely not the normal path lol) because he was a first author on a particularly good CRISPR paper. On one hand - trend chasing and bubbles have their obvious downsides. On the other hand - it does mean a lot of resources get funneled into new interesting areas when something cool pops up. But on the original hand - trend chasing and bubbles, welcome to humans on earth i guess. But yeah in terms of how you know about it - you'll know it's quite obvious who's getting money and tenure.

Infectious disease in particular is going to have a really hard time. No market for it, no industry demand. Investments there are already winding down in general: https://www.fiercebiotech.com/biotech/johnson-and-johnson-sh....